Balance Capital Partners’s Ginkgo Bioworks DNA Stock Holding History

Balance Capital Partners’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.97M	Buy	+199,009	New	+$1.66M	1.42%	10

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Balance Capital Partners's DNA Position: Q2 2026 in Review

Balance Capital Partners opened a new position in Ginkgo Bioworks (DNA) in Q2 2026: 199,009 shares worth $1.97M. The stake represents 1.42% of the portfolio and ranks #10 among its holdings.

184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Balance Capital Partners held 199,009 shares of Ginkgo Bioworks worth $1.97M as of Q2 2026.
Ginkgo Bioworks was a new Balance Capital Partners position in Q2 2026.
Ginkgo Bioworks made up 1.42% of Balance Capital Partners's portfolio in Q2 2026, its #10 holding.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Balance Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.